Mr. Ryosuke Suzuki, Embryologist at Kanagawa Ladies Clinic, Publishes Research Paper in Journal of Mammalian Ova Research

Clinical Insights on Embryo Cryopreservation Protocols Expected to Support Improved Pregnancy Outcomes and Reduced Burden in Fertility Treatment

IRVINE, Calif. --SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization providing management support across a wide range of healthcare fields, today announced that Mr. Ryosuke Suzuki, an embryologist at Kanagawa Ladies Clinic, a fertility specialty clinic under SBC Medical's management support, has had his research paper published in the Journal of Mammalian Ova Research (Vol. 43, No. 1, 2026), an academic journal of the Japan Society of Ova Research. The paper, titled "Cryopreservation and Thawing Protocols for Human Cleavage-Stage Embryos and Blastocysts: Practical Techniques and Clinical Refinements," presents the latest methodologies and clinical refinements implemented at the clinic for embryo cryopreservation, a critical technique in fertility treatment. The findings are expected to contribute to improved pregnancy rates and reduced physical, emotional, and financial burden for customers undergoing fertility treatment.

Embryo cryopreservation has become an indispensable technology in modern fertility treatment. Advances in this field have enabled the reduction of risks associated with multiple pregnancies and the avoidance of complications such as ovarian hyperstimulation syndrome (OHSS)*2. Furthermore, transferring frozen embryos at carefully timed intervals has been associated with improved pregnancy success rates.

The paper systematically organizes the clinical practices and refinements employed at Kanagawa Ladies Clinic, building upon the "Ready to Vitri/Warm Kit" cryopreservation and thawing methodology. It also introduces recently reported simplified protocols, underscoring the importance of each medical institution selecting approaches best suited to its own clinical environment. The research is expected to support the broader adoption of safe and effective cryopreservation and thawing techniques, ultimately contributing to improved pregnancy outcomes and reduced burden for customers undergoing fertility treatment.

As innovation continues to transform the medical field, the importance of knowledge sharing and academic collaboration, beyond clinical practice alone, continues to grow. Addressing increasingly diverse customer needs requires not only the adoption of cutting-edge technologies, but also a broad perspective and flexible approach. SBC Medical remains committed to promoting advanced initiatives through academic activities and collaboration with research institutions, and to enhancing the safety, transparency, and sustained value of healthcare.

*1 Embryo cryopreservation: A technique in which a fertilized egg (embryo) is frozen and later thawed and transferred to the uterus at an appropriate time.

*2 Ovarian hyperstimulation syndrome (OHSS): A complication in which the ovaries react excessively to ovulation-inducing medications, potentially causing ascites, pleural effusion, and other symptoms.

Publication Details
Journal: Journal of Mammalian Ova Research (Japan Society of Ova Research)
Volume/Issue: Vol. 43, No. 1, pp. 3–12, 2026
Paper Title: "Cryopreservation and Thawing Protocols for Human Cleavage-Stage Embryos and Blastocysts: Practical Techniques and Clinical Refinements"

About Kanagawa Ladies Clinic
Kanagawa Ladies Clinic is a fertility and in vitro fertilization (IVF) specialty clinic based in Yokohama, Kanagawa Prefecture. Operating under the motto "A clinic that is accessible, convenient, and easy to visit," the clinic provides treatment tailored to the individual condition and life stage of each customer. Offering a broad range of services from general fertility care to advanced reproductive medicine — including IVF and embryo transfer — the clinic operates under a highly specialized medical framework. The clinic also places strong emphasis on ease of access and efficient care delivery, and is dedicated to reducing the physical, emotional, and financial burden on its customers.

Official Website: https://www.klc.jp/

About SBC Medical Group Holdings Incorporated
SBC Medical Group Holdings Incorporated is a Medical Services Organization　providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.

For more information, visit https://sbc-holdings.com
For more insights and updates from SBC Medical, follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

Contacts
Hikaru Fukui / Head of IR Department; E-mail: ir@sbc-holdings.com
Akiko Wakiyama / Chief Public Relations Officer; E-mail: pr@sbc.or.jp